Form 4: Clover Health CEO Sells Shares for Tax Obligations

Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, disposed of 71,432 shares of Class A Common Stock to cover tax obligations related to RSU vesting.

Summary

• Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (CLOV), reported a disposition of 71,432 shares of Class A Common Stock.
• The transaction occurred on October 15, 2025, at a price of $2.8 per share.
• This disposition was an automatic withholding to cover tax obligations due to the vesting of 25% of restricted stock units (RSUs) originally granted on October 15, 2024.
• Following this transaction, Jamie L. Reynoso beneficially owns 2,971,740 shares of Class A Common Stock.
• The remaining RSUs are scheduled to vest quarterly in equal installments of 6.25%, with the final vesting date on October 15, 2028, contingent on continued service.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax withholding related to RSU vesting, which is a neutral event and does not indicate a change in company fundamentals or executive sentiment towards the stock beyond compensation structure.

Positives

• The vesting of restricted stock units (RSUs) represents earned compensation for the executive, reflecting their continued service and contribution to the company.

Future Outlook

The remaining restricted stock units (RSUs) granted to Jamie L. Reynoso are scheduled to vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to continued service.

Industry Context

The disposition of shares to cover tax obligations upon the vesting of restricted stock units (RSUs) is a standard and routine practice for executives receiving equity compensation across various industries. This mechanism allows executives to satisfy tax liabilities incurred from the RSU vesting without needing to use personal funds.

Comparison to Industry Standards

• This transaction is a common occurrence in executive compensation packages, aligning with standard practices seen in technology and healthcare companies where equity awards like RSUs are a significant component of remuneration.
• The use of 'sell-to-cover' for tax obligations is a widely accepted method, similar to practices at companies like Apple, Microsoft, or Google, where executives frequently report such dispositions upon equity vesting.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not a signal of executive selling due to lack of confidence.
• Employees: No direct impact mentioned.

Next Steps

• Continued quarterly vesting of remaining restricted stock units (RSUs) until October 15, 2028, subject to Jamie L. Reynoso's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by an executive to cover tax obligations arising from RSU vesting. Such transactions are a standard part of executive compensation and do not typically reflect a change in the executive's outlook on the company or its future prospects. Therefore, it provides no new fundamental information to warrant a change in investment stance, leading to a 'hold' recommendation.

Keywords

CLOV, Clover Health, Form 4, Insider Transaction, RSU Vesting, Tax Withholding, Jamie L. Reynoso, Executive Compensation